Steven I Sherman

List of Publications by Year
in descending order

180 papers	42,823 citations	7568 77 h-index	5255 165 g-index
185 all docs	185 docs citations	185 times ranked	21237 citing authors

#	Article	IF	Citations
1	Impact of baseline tumor burden on overall survival in patients with radioiodineâ€refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial. Cancer, 2022, 128, 2281-2287.	4.1	8
2	ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of RET, VEGFR2, and IGFBP2. Molecular Cancer Therapeutics, 2021, 20, 665-675.	4.1	10
3	Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib. Thyroid, 2021, 31, 1226-1234.	4.5	24
4	Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer. Journal of Clinical Oncology, 2021, 39, 2359-2366.	1.6	64
5	Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 1126-1138.	10.7	136
6	Distant Metastases From Childhood Differentiated Thyroid Carcinoma: Clinical Course and Mutational Landscape. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1683-1697.	3.6	42
7	RAI Refractory Differentiated Thyroid Cancer with Multiple-Organ Progressive Disease. , 2021, , 261-268.		0
8	RAI-Refractory, Advanced Differentiated Thyroid Cancer Receiving Kinase Inhibitor Treatment: Checking for Drug-Drug Interactions. , 2021, , 303-308.		0
9	Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. ESMO Open, 2020, 5, e000799.	4.5	45
10	The De Novo Detection of Anti-Thyroglobulin Antibodies and Differentiated Thyroid Cancer Recurrence. Thyroid, 2020, 30, 1490-1495.	4.5	12
11	Genetic profiling as a clinical tool in advanced parathyroid carcinoma. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1977-1986.	2.5	30
12	Risk Haplotypes Uniquely Associated with Radioiodine-Refractory Thyroid Cancer Patients of High African Ancestry. Thyroid, 2019, 29, 530-539.	4.5	8
13	A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. Clinical Cancer Research, 2019, 25, 5475-5484.	7.0	17
14	Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling. Head and Neck, 2019, 41, 1928-1934.	2.0	21
15	Combinations of Tyrosine Kinase Inhibitor and ERAD Inhibitor Promote Oxidative Stressâ€“Induced Apoptosis through ATF4 and KLF9 in Medullary Thyroid Cancer. Molecular Cancer Research, 2019, 17, 751-760.	3.4	22
16	Novel Drug Treatments of Progressive Radioiodine-Refractory Differentiated Thyroid Cancer. Endocrinology and Metabolism Clinics of North America, 2019, 48, 253-268.	3.2	18
17	Editor's Note: Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid Cancer. Clinical Cancer Research, 2019, 25, 4862-4862.	7.0	2
18	A phase 3 (COSMIC-311), randomized, double-blind, placebo-controlled study of cabozantinib in patients with radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) who have progressed after prior VEGFR-targeted therapy.. Journal of Clinical Oncology, 2019, 37, TPS6097-TPS6097.	1.6	8

#	Article	IF	Citations
19	EVOLUTION OF TARGETED THERAPIES FOR THYROID CARCINOMA. Transactions of the American Clinical and Climatological Association, 2019, 130, 255-265.	0.5	2
20	Pioglitazone Therapy of PAX8-PPARÎ³ Fusion Protein Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1277-1281.	3.6	22
21	Treatmentâ€emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Cancer, 2018, 124, 2365-2372.	4.1	77
22	Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3698-3705.	3.6	91
23	New (Medical) Treatment for Thyroid Carcinoma. Endocrinology, 2018, , 645-670.	0.1	0
24	New (Medical) Treatment for Thyroid Carcinoma. Endocrinology, 2018, , 1-26.	0.1	0
25	American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Thyroid, 2017, 27, 481-483.	4.5	273
26	Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. European Journal of Cancer, 2017, 75, 213-221.	2.8	59
27	Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine, 2017, 56, 121-128.	2.3	82
28	Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3591-3599.	3.6	63
29	Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. Oncology, 2016, 90, 339-346.	1.9	43
30	Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4103-4109.	3.6	78
31	Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. Cancer, 2016, 122, 3856-3864.	4.1	81
32	Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2016, 17, 1272-1282.	10.7	290
33	RAI-Refractory Differentiated Thyroid Cancer with Multiple Organ Progressive Disease. , 2016, , 279-285.		0
34	2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 2016, 26, 1-133.	4.5	10,674
35	A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. Clinical Cancer Research, 2016, 22, 44-53.	7.0	193
36	A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodineâ€refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer, 2015, 121, 2749-2756.	4.1	159

#	Article	IF	Citations
37	Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodineâ€refractory differentiated thyroid cancer. Cancer Science, 2015, 106, 1714-1721.	3.9	111
38	Follicular cell-derived thyroid cancer. Nature Reviews Disease Primers, 2015, 1, 15077.	30.5	88
39	Unique Characteristics and Outcomes of Patients Diagnosed With Both Primary Thyroid and Primary Renal Cell Carcinoma. Endocrine Practice, 2015, 21, 461-467.	2.1	3
40	Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. New England Journal of Medicine, 2015, 372, 621-630.	27.0	1,526
41	Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancerâ€"Related Diarrhea and Its Effects on Quality of Life: A Pilot Study. Thyroid, 2015, 25, 1085-1090.	4.5	22
42	Reassessing the NTCTCS Staging Systems for Differentiated Thyroid Cancer, Including Age at Diagnosis. Thyroid, 2015, 25, 1097-1105.	4.5	20
43	Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987â€"2012. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3270-3279.	3.6	137
44	BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF-Mutant Thyroid Cancer. Thyroid, 2015, 25, 71-77.	4.5	189
45	Efficacy and Tolerability of Vemurafenib in Patients with BRAFV600E -Positive Papillary Thyroid Cancer: M.D. Anderson Cancer Center Off Label Experience. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E77-E81.	3.6	109
46	Effect of age and lenvatinib treatment on overall survival for patients with ¹³¹I-refractory differentiated thyroid cancer in SELECT.. Journal of Clinical Oncology, 2015, 33, 6048-6048.	1.6	8
47	Integrated Genomic Characterization of Papillary Thyroid Carcinoma. Cell, 2014, 159, 676-690.	28.9	2,318
48	A Phase I Study of Cabozantinib (XL184) in Patients with Differentiated Thyroid Cancer. Thyroid, 2014, 24, 1508-1514.	4.5	77
49	Efficacy and Tolerability of Different Starting Doses of Sorafenib in Patients With Differentiated Thyroid Cancer. Oncologist, 2014, 19, 477-482.	3.7	24
50	Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet, The, 2014, 384, 319-328.	13.7	1,295
51	Prevalence by Age and Predictors of Medullary Thyroid Cancer in Patients with Lower Risk Germline RET Proto-Oncogene Mutations. Thyroid, 2014, 24, 1096-1106.	4.5	40
52	Role of Salvage Targeted Therapy in Differentiated Thyroid Cancer Patients Who Failed First-Line Sorafenib. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2086-2094.	3.6	87
53	Prognosis of Differentiated Thyroid Cancer in Relation to Serum Thyrotropin and Thyroglobulin Antibody Status at Time of Diagnosis. Thyroid, 2014, 24, 35-42.	4.5	117
54	Thyroid Carcinoma, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1671-1680.	4.9	147

#	Article	IF	Citations
55	A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with ¹³¹I-refractory differentiated thyroid cancer (SELECT).. Journal of Clinical Oncology, 2014, 32, LBA6008-LBA6008.	1.6	23
56	A phase 1 trial of vandetanib (multikinase inhibitor of EGFR, VEGFR, and RET) in combination with everolimus (mTOR inhibitor) in patients with advanced malignancies.. Journal of Clinical Oncology, 2014, 32, TPS2639-TPS2639.	1.6	0
57	Lessons learned and questions unanswered from use of multitargeted kinase inhibitors in medullary thyroid cancer. Oral Oncology, 2013, 49, 707-710.	1.5	31
58	The Noninvestigational Use of Tyrosine Kinase Inhibitors in Thyroid Cancer: Establishing a Standard for Patient Safety and Monitoring. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 31-42.	3.6	80
59	Clinical Responses to Vemurafenib in Patients with Metastatic Papillary Thyroid Cancer Harboring BRAF^{V600E}Mutation. Thyroid, 2013, 23, 1277-1283.	4.5	184
60	Cabozantinib in Progressive Medullary Thyroid Cancer. Journal of Clinical Oncology, 2013, 31, 3639-3646.	1.6	989
61	Diagnosis and management of differentiated thyroid cancer using molecular biology. Laryngoscope, 2013, 123, 1059-1064.	2.0	47
62	Evolving Approaches to Patients with Advanced Differentiated Thyroid Cancer. Endocrine Reviews, 2013, 34, 439-455.	20.1	105
63	The Role of Recombinant Human Thyrotropin for Diagnostic Monitoring of Patients with Differentiated Thyroid Cancer. Endocrine Practice, 2013, 19, 157-161.	2.1	12
64	Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial.. Journal of Clinical Oncology, 2013, 31, 4-4.	1.6	23
65	Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial.. Journal of Clinical Oncology, 2013, 31, 4-4.	1.6	48
66	The Role of Recombinant Human Thyrotropin for Diagnostic Monitoring of Patients with Differentiated Thyroid Cancer. Endocrine Practice, 2013, 1, 1-17.	2.1	0
67	In Papillary Thyroid Cancer, Preoperative Central Neck Ultrasound Detects Only Macroscopic Surgical Disease, But Negative Findings Predict Excellent Long-Term Regional Control and Survival. Thyroid, 2012, 22, 347-355.	4.5	105
68	Applying new clinicopathological characteristics to prognostication in advanced thyroid carcinoma. Endocrine-Related Cancer, 2012, 19, C19-C22.	3.1	7
69	ENDOCRINE TUMOURS: Approach to the patient with advanced differentiated thyroid cancer. European Journal of Endocrinology, 2012, 166, 5-11.	3.7	104
70	The Impact of Age and Gender on Papillary Thyroid Cancer Survival. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E878-E887.	3.6	162
71	An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline.. Journal of Clinical Oncology, 2012, 30, 5508-5508.	1.6	73
72	Lenvatinib treatment of advanced RAI-refractory differentiated thyroid cancer (DTC): Cytokine and angiogenic factor (CAF) profiling in combination with tumor genetic analysis to identify markers associated with response.. Journal of Clinical Oncology, 2012, 30, 5518-5518.	1.6	17

#	Article	IF	Citations
73	Antitumor activity of cabozantinib (XL184) in a cohort of patients (pts) with differentiated thyroid cancer (DTC).. Journal of Clinical Oncology, 2012, 30, 5547-5547.	1.6	18
74	Preoperative Lateral Neck Ultrasonography as a Long-term Outcome Predictor in Papillary Thyroid Cancer. JAMA Otolaryngology, 2011, 137, 157.	1.2	45
75	Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer, 2011, 11, 349.	2.6	84
76	Inhibition of pituitary tumorâ€transforming geneâ€1 in thyroid cancer cells by drugs that decrease specificity proteins. Molecular Carcinogenesis, 2011, 50, 655-667.	2.7	35
77	Targeted therapies for thyroid tumors. Modern Pathology, 2011, 24, S44-S52.	5.5	75
78	Inhibition of the Ras/Raf/MEK/ERK and RET Kinase Pathways with the Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Medullary and Differentiated Thyroid Malignancies. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 997-1005.	3.6	100
79	Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer. Journal of Clinical Oncology, 2011, 29, 2660-2666.	1.6	504
80	The Safety of Incretin-Based Therapiesâ€"Review of the Scientific Evidence. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2027-2031.	3.6	143
81	Long-Term Outcome of Comprehensive Central Compartment Dissection in Patients with Recurrent/Persistent Papillary Thyroid Carcinoma. Thyroid, 2011, 21, 1309-1316.	4.5	81
82	Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy. Head and Neck, 2010, 32, 829-836.	2.0	80
83	Thyroid Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 1228-1274.	4.9	194
84	Medullary Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 512-530.	4.9	70
85	Targeted therapy of thyroid cancer. Biochemical Pharmacology, 2010, 80, 592-601.	4.4	70
86	Genetic alterations in the RAS/RAF/mitogenâ€activated protein kinase and phosphatidylinositol 3â€kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma. Cancer, 2010, 116, 2974-2983.	4.1	70
87	Should Papillary Thyroid Carcinoma Be Observed?: A Word of Caution. JAMA Otolaryngology, 2010, 136, 444.	1.2	6
88	Radioiodine Therapy in Patients with Stage I Differentiated Thyroid Cancer. Thyroid, 2010, 20, 1423-1424.	4.5	78
89	Biomarkers as Predictors of Response to Treatment with Motesanib in Patients with Progressive Advanced Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 5018-5027.	3.6	87
90	Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits. Diabetes Care, 2010, 33, 428-433.	8.6	281

#	Article	IF	Citations
91	Treatment with Tyrosine Kinase Inhibitors for Patients with Differentiated Thyroid Cancer: the M. D. Anderson Experience. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2588-2595.	3.6	183
92	Molecularly Targeted Therapies for Thyroid Cancers. Endocrine Practice, 2009, 15, 605-611.	2.1	11
93	Clinical Trials for Progressive Differentiated Thyroid Cancer: Patient Selection, Study Design, and Recent Advances. Thyroid, 2009, 19, 1393-1400.	4.5	80
94	The Successful Use of Sorafenib to Treat Pediatric Papillary Thyroid Carcinoma. Thyroid, 2009, 19, 407-412.	4.5	54
95	Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer. Journal of Clinical Oncology, 2009, 27, 3794-3801.	1.6	337
96	Development and Initial Validation of the Thyroid Cancer Module of the M. D. Anderson Symptom Inventory. Oncology, 2009, 76, 59-68.	1.9	46
97	Assessment of the Incremental Value of Recombinant Thyrotropin Stimulation before 2-[18F]-Fluoro-2-Deoxy-<scp>d</scp>-Glucose Positron Emission Tomography/Computed Tomography Imaging to Localize Residual Differentiated Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1310-1316.	3.6	132
98	Follow-Up of Low-Risk Differentiated Thyroid Cancer Patients Who Underwent Radioiodine Ablation of Postsurgical Thyroid Remnants after Either Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4171-4179.	3.6	78
99	Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies. Clinical Cancer Research, 2009, 15, 7061-7068.	7.0	78
100	Phase I Clinical Trials in 56 Patients with Thyroid Cancer: The M. D. Anderson Cancer Center Experience. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4423-4432.	3.6	32
101	Advances in Chemotherapy of Differentiated Epithelial and Medullary Thyroid Cancers. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1493-1499.	3.6	101
102	Diabetes insipidus and panhypopituitarism due to intrasellar metastasis from medullary thyroid cancer. Head and Neck, 2009, 31, 419-423.	2.0	23
103	Hypothyroidism in older patients with head and neck cancer after treatment with radiation: A populationâ€based study. Head and Neck, 2009, 31, 1031-1038.	2.0	30
104	Approach and safety of comprehensive central compartment dissection in patients with recurrent papillary thyroid carcinoma. Head and Neck, 2009, 31, 1152-1163.	2.0	78
105	Association between hypothyroidism and hepatocellular carcinoma: A case-control study in the United States. Hepatology, 2009, 49, 1563-1570.	7.3	141
106	Postoperative External Beam Radiotherapy for Differentiated Thyroid Cancer: Outcomes and Morbidity With Conformal Treatment. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1083-1091.	0.8	143
107	Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 2009, 19, 1167-1214.	4.5	6,039
108	Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma. Human Pathology, 2009, 40, 827-833.	2.0	28

#	Article	IF	Citations
109	Erratum to â€œDetection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinomaâ€•[Hum Pathol 40 (2009) 827-833]. Human Pathology, 2009, 40, 1212.	2.0	0
110	Tyrosine kinase inhibitors and the thyroid. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 713-722.	4.7	40
111	Endocrine Complications of Head and Neck Surgery. , 2009, , 85-103.		0
112	Recurrence After Treatment of Micropapillary Thyroid Cancer. Thyroid, 2009, 19, 1043-1048.	4.5	185
113	The Laboratory Approach to Thyroid Disorders. , 2009, , 1-38.		1
114	Long-term eradication of locally recurrent invasive follicular thyroid carcinoma after taxane-based concomitant chemoradiotherapy. Anticancer Research, 2009, 29, 4665-71.	1.1	2
115	Postoperative radiotherapy for advanced medullary thyroid cancerâ€"Local disease control in the modern era. Head and Neck, 2008, 30, 883-888.	2.0	78
116	Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Human Pathology, 2008, 39, 15-20.	2.0	37
117	Early Clinical Studies of Novel Therapies for Thyroid Cancers. Endocrinology and Metabolism Clinics of North America, 2008, 37, 511-524.	3.2	47
118	Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer. New England Journal of Medicine, 2008, 359, 31-42.	27.0	446
119	Phosphatidylinositol 3-Kinase/Akt and Ras/Raf-Mitogen-Activated Protein Kinase Pathway Mutations in Anaplastic Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 278-284.	3.6	177
120	Four Patients with Cutaneous Metastases from Medullary Thyroid Cancer. Thyroid, 2008, 18, 901-905.	4.5	20
121	Can serum thyroglobulin levels predict patient outcome after treatment of differentiated thyroid carcinoma?. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 510-511.	2.8	1
122	Single-Dose Rexinoid Rapidly and Specifically Suppresses Serum Thyrotropin in Normal Subjects. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 124-130.	3.6	45
123	Subacute Thyroiditis Causing Thyroid Storm. Thyroid, 2007, 17, 283-283.	4.5	11
124	Mosaicism in von Hippelâ€Lindau disease: an event important to recognize. Journal of Cellular and Molecular Medicine, 2007, 11, 1408-1415.	3.6	22
125	Thyroid Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2007, 5, 568.	4.9	42
126	Outcomes of Patients with Differentiated Thyroid Carcinoma Following Initial Therapy. Thyroid, 2006, 16, 1229-1242.	4.5	593

#	Article	IF	Citations
127	Radioiodine Ablation of Thyroid Remnants after Preparation with Recombinant Human Thyrotropin in Differentiated Thyroid Carcinoma: Results of an International, Randomized, Controlled Study. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 926-932.	3.6	405
128	Management of Thyroid Nodules Detected at US. Ultrasound Quarterly, 2006, 22, 231-238.	0.8	138
129	Cancer disparities and thyroid carcinoma. Current Opinion in Endocrinology, Diabetes and Obesity, 2006, 13, 451-454.	0.6	0
130	Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce. Thyroid, 2006, 16, 109-142.	4.5	1,857
131	Phase II Study of Celecoxib in Metastatic Differentiated Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2201-2204.	3.6	54
132	A Comparison of Short-Term Changes in Health-Related Quality of Life in Thyroid Carcinoma Patients Undergoing Diagnostic Evaluation with Recombinant Human Thyrotropin Compared with Thyroid Hormone Withdrawal. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 878-884.	3.6	176
133	Thyrotoxicosis after Denileukin Diftitox Therapy in Patients with Mycosis Fungoides. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2205-2208.	3.6	30
134	Thyroid Lymphoma. , 2006, , 615-619.		1
135	Anaplastic Carcinoma. , 2006, , 629-632.		7
136	Anaplastic Carcinoma. , 2006, , 647-649.		1
137	Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 2006, .	4.5	9
138	Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. Journal of Nuclear Medicine, 2006, 47, 648-54.	5.0	209
139	RETProto-Oncogene: A Review and Update of Genotypeâ€“Phenotype Correlations in Hereditary Medullary Thyroid Cancer and Associated Endocrine Tumors. Thyroid, 2005, 15, 531-544.	4.5	269
140	Why Thyroid Cancer?. Thyroid, 2005, 15, 303-304.	4.5	11
141	Management of Thyroid Nodules Detected at US: Society of Radiologists in Ultrasound Consensus Conference Statement. Radiology, 2005, 237, 794-800.	7.3	1,055
142	Thyroid Cancer Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2005, 3, 404.	4.9	47
143	Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid Cancer. Clinical Cancer Research, 2004, 10, 8594-8602.	7.0	154
144	Preventable reoperations for persistent and recurrent papillary thyroid carcinoma. Surgery, 2004, 136, 1183-1191.	1.9	89

#	Article	IF	Citations
145	Surgical management of hereditary pheochromocytoma1 1No competing interests declared.. Journal of the American College of Surgeons, 2004, 198, 525-534.	0.5	120
146	Parathyroid carcinoma: A 22-year experience. Head and Neck, 2004, 26, 716-726.	2.0	233
147	Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1371-1377.	6.4	95
148	Prognostic factors in patients with HÃ¼rthle cell neoplasms of the thyroid. Cancer, 2003, 97, 1186-1194.	4.1	175
149	Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery, 2003, 134, 890-899.	1.9	77
150	Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery, 2003, 134, 946-954.	1.9	480
151	Etiology, Diagnosis, and Treatment Recommendations for Central Hypothyroidism Associated with Bexarotene Therapy for Cutaneous T-Cell Lymphoma. Clinical Lymphoma and Myeloma, 2003, 3, 249-252.	2.1	58
152	Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients. American Journal of Surgery, 2003, 186, 702-710.	1.8	239
153	Potential role for intraoperative gamma probe identification of normal parathyroid glands. American Journal of Surgery, 2003, 186, 711-717.	1.8	12
154	A Consensus Report of the Role of Serum Thyroglobulin as a Monitoring Method for Low-Risk Patients with Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1433-1441.	3.6	605
155	Thyroid carcinoma. Lancet, The, 2003, 361, 501-511.	13.7	895
156	Multiple Endocrine Neoplasia Type 2. Archives of Surgery, 2003, 138, 409.	2.2	196
157	Socioeconomic Factors and the Presentation, Management, and Outcome of Patients with Differentiated Thyroid Carcinoma. Thyroid, 2002, 12, 1009-1016.	4.5	19
158	Optimizing the Outcomes of Adjuvant Radioiodine Therapy in Differentiated Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4059-4062.	3.6	12
159	Improving the yield of preoperative parathyroid localization: Technetium Tc 99m-sestamibi imaging after thyroid suppression. Surgery, 2002, 132, 968-975.	1.9	31
160	Optimal treatment strategy in patients with papillary thyroid cancer: A decision analysis. Surgery, 2001, 130, 921-930.	1.9	108
161	Thyroid Cancer: 1999 Update and Evaluation of Solitary Thyroid Nodules. Annals of Surgical Oncology, 2000, 7, 376-398.	1.5	39
162	Thyroid Microcarcinoma: Prevalence, Prognosis, and Management. Endocrine Practice, 1999, 5, 148-156.	2.1	37

#	Article	IF	Citations
163	A Comparison of Recombinant Human Thyrotropin and Thyroid Hormone Withdrawal for the Detection of Thyroid Remnant or Cancer1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 3877-3885.	3.6	447
164	Central Hypothyroidism Associated with Retinoid X Receptorâ€“Selective Ligands. New England Journal of Medicine, 1999, 340, 1075-1079.	27.0	286
165	Toward a standard clinicopathologic staging approach for differentiated thyroid carcinoma. , 1999, 16, 12-15.		27
166	Surgical Strategy for the Treatment of Medullary Thyroid Carcinoma. Annals of Surgery, 1999, 230, 697.	4.2	129
167	Prospective multicenter study of thyroid carcinoma treatment. , 1998, 83, 1012-1021.		347
168	The risks of thyroidectomy. Journal of General Internal Medicine, 1998, 13, 60-61.	2.6	12
169	Unknown primary cancer presenting as an adrenal mass: Frequency and implications for diagnostic evaluation of adrenal incidentalomas. Surgery, 1998, 124, 1115-1122.	1.9	114
170	Effects of Pharmacological Fiber Supplements on Levothyroxine Absorption. Thyroid, 1998, 8, 667-671.	4.5	37
171	Thyrotropin Suppression and Disease Progression in Patients with Differentiated Thyroid Cancer: Results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid, 1998, 8, 737-744.	4.5	293
172	Prognosis and Treatment of Brain Metastases in Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3637-3642.	3.6	237
173	Prognosis and Treatment of Brain Metastases in Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3637-3642.	3.6	68
174	Augmented Hepatic and Skeletal Thyromimetic Effects of Tiratricol in Comparison with Levothyroxine. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2153-2158.	3.6	54
175	Clinical and socioeconomic predispositions to complicated thyrotoxicosis: A predictable and preventable syndrome?. American Journal of Medicine, 1996, 101, 192-198.	1.5	33
176	Follicular variant of papillary thyroid carcinoma. A clinicopathologic study. Cancer, 1994, 73, 424-431.	4.1	177
177	Sucralfate causes malabsorption of L-thyroxine. American Journal of Medicine, 1994, 96, 531-535.	1.5	84
178	Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 1994, 78, 629-634.	3.6	140
179	Percutaneous transluminal coronary angioplÃ¡sty in hypothyroidism. American Journal of Medicine, 1991, 90, 367-370.	1.5	2
180	Percutaneous transluminal coronary angioplasty in hypothyroidism. American Journal of Medicine, 1991, 90, 367-370.	1.5	21